View/Open

Author
Amirah, Lufthia

Advisor
Prof . Dr. apt. Anderanus Andaja Soemardji., D.E.A,
apt. Nisa Yulianti Suprahman., S.Farm, M.Sc,

Koleksi
Farmasi

Publisher

The Case Fatality Rate (CFR) due to COVID-19 in Indonesia is ranked the second highest in Asia. As an immunosuppressant and anti-inflammatory, corticosteroids are useful in improving immunopathology in viral infections. The corticosteroids recommended by WHO and Indonesian guidelines are hydrocortisone, dexamethasone, and methylprednisolone. This study aims to compare the type, dose, and duration of corticosteroid administration with the WHO 2022 COVID-19 management guidelines and the 4th edition of 2022 COVID-19 management guidelines in Indonesia, and the types of corticosteroids that are effective against clinical outcomes and inflammation indicators. The database used in this research is PubMed. The selection results on the PubMed database obtained 15 journals that met the inclusion and exclusion criteria. The results of reporting in 15 journals show that there are differences in the dose and duration given compared to WHO guidelines and Indonesian guidelines. Hydrocortisone used is a dose of 50 mg-200 mg/day for 7-14 days, dexamethasone dose of 6 mg-20 mg/day for 5-10 days, and methylprednisolone dose of 30 mg-500 mg/day for 3-10 days. Methylprednisolone has been shown to have a better effect than hydrocortisone and dexamethasone in terms of recovery time, length of stay, duration of use of breathing apparatus, mortality rate, and inflammation indicators. Keywords: literature review, COVID-19, corticosteroids, anti-inflammatory

URI
https://repo.itera.ac.id/depan/submission/SB2301160033

Keyword